Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions reflect a balanced curiosity and involvement, with examples such as references to study names like CANVAS and CREDENCE, and concerns about safety signals like amputations, which show both analytical interest and cautious engagement. The tone ranges from clinical updates to safety debates, emphasizing the article's relevance in ongoing medical conversations.
The discussions show mixed opinions, with some recognizing the benefits of canagliflozin but also raising safety concerns like amputation risks.
The posts demonstrate moderate curiosity about the study's findings and implications, often referencing specific trials like CANVAS and CREDENCE.
Many posts include detailed references to trial results, safety considerations, and ongoing debates, indicating a higher level of engagement.
The discussions highlight that the article influences clinical considerations and safety debates, suggesting a noteworthy but not transformative impact.
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWCN
#ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further reading: https://t.co/gZYEfZthJV https://t.co/pxg7VuTPmM https://t.co/TkL1bUZAzh https://t.co/jiReouHd2o https://t.co/afT6tGHSqa https://t.co/0aWpT6gJc6 https://t.co/KSEVGqkcZD
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephpearls #NephJC
#Canagliflozin and Cardiovascular and Renal Events in #T2D Available in France but I’m convinced that most #HCP forgot #CREDENCE and #CANVAS studies … https://t.co/uhrDb9aOiM
1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a brief overview of CANVAS & CREDENCE Trials to review why an SGLT2i was started. CANVAS Trial: https://t.co/mfw2cI9buz CREDENCE Trial: https://t.co/2rGjYf92WQ
Whether the increased risk of lower limb amputation in the CANVAS Program was due to differing trial populations or protocols, or to chance remains unclear #NKFClinicals
Canagliflozin lowers blood sugar and blood pressure, reducing serious cardiovascular risks in high-risk type 2 diabetes patients. While it benefits kidney health, there is an increased risk of amputation. Learn about…
Dr. Bruce Neal, a leading cardiologist, explores the cardiovascular implications of low sodium and high potassium diets. He presents findings from the 2021 SSASS Study, which involved 20,995 high-risk patients assessing…
RT @SABOURETCardio: #Canagliflozin and Cardiovascular and Renal Events in #T2D Available in France but I’m convinced that most #HCP forgot…
RT @SABOURETCardio: #Canagliflozin and Cardiovascular and Renal Events in #T2D Available in France but I’m convinced that most #HCP forgot…
#Canagliflozin and Cardiovascular and Renal Events in #T2D Available in France but I’m convinced that most #HCP forgot #CREDENCE and #CANVAS studies … https://t.co/uhrDb9aOiM
@kksft @KobaKobauro @muscle_penguin_ SGLT2iは心臓病の患者に対してポジティブな効果があります。 SGLT2iはグルコースを尿から排出することでインスリンを下げケトン体を増やす作用があります。 腎臓疾患にも効果があります。 https://t.co/Jh5XhfMR7N https://t.co/nz6ZXSXZUz
#ゆかこメモ
@Tacothenation1 No specific threshold. In CANVAS they had to have an A1c <10.5 https://t.co/3hXZUMARLB
@kidney_boy https://t.co/Dw1oq3Pjo6
24b) Other #DPP4i, #basal #insulin, and α-GI are neutral but and @GLP1 RAs have modest benefit from meta-analysis. #SGLT2i show consistent and robust benefits. Consider
@abledoc Why it would be increasing risk for amputation? Canagliflozin lowers risk of CVD, but increases risk of amputation https://t.co/f2DFRV7wbK
CANVAS: Among patients with T2D and high CV risk, canagliflozin was associated with lower CV and renal events but higher risk of amputation #UMKCRCT https://t.co/SxOGWqDwtj
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
RT @ISNkidneycare: #ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further rea…
#ISNWebinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Further reading: https://t.co/gZYEfZthJV https://t.co/pxg7VuTPmM https://t.co/TkL1bUZAzh https://t.co/jiReouHd2o https://t.co/afT6tGHSqa https://t.co/0aWpT6gJc6 https://t.co/KSEVGqkcZD
https://t.co/PraSDuCNkG
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes - PubMed https://t.co/JaZyj6KP3q
そういえば、読んだことなかった https://t.co/kuIn6pbC62
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephm…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephm…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephm…
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephmadness 2️⃣
RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…
RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…
RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…
RT @MelBreggs: 1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a bri…
1/3-Day 8: Cardiology started an SGLT2 inhibitor on a patient for the first time. Thought it would be good to give a brief overview of CANVAS & CREDENCE Trials to review why an SGLT2i was started. CANVAS Trial: https://t.co/mfw2cI9buz CREDENCE Trial: https://t.co/2rGjYf92WQ
[Solution]Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes https://t.co/lM78LDCx4J
RT @edgarvlermamd: Whether the increased risk of lower limb amputation in the CANVAS Program was due to differing trial populations or prot…
@Joe_Vassalotti CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephpearls
RT @NEJM: Original Article: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) https://t.co/aEGa1ggSpw #ADA2017
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes To know more : https://t.co/rtMD0TxgHr #cardiologyconference #cardiologymeeting #cardiologistsconference #cardiovascular #cardiacdisease #cardiacmuscle https://t.co/rmPUPgtzf0
RT @edgarvlermamd: Whether the increased risk of lower limb amputation in the CANVAS Program was due to differing trial populations or prot…
RT @edgarvlermamd: Whether the increased risk of lower limb amputation in the CANVAS Program was due to differing trial populations or prot…
Whether the increased risk of lower limb amputation in the CANVAS Program was due to differing trial populations or protocols, or to chance remains unclear #NKFClinicals
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephp…
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #Nephpearls #NephJC
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
@kidneydoc101 @DrGavinDreyer @toates_19 @OK_Kidney @Ashidotic Likely significantly underpowered. The excess risk of amputation w Canagliflozin was in the combined CANVAS trials, n=10,000 https://t.co/4HtuaLYrip
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
RT @edgarvlermamd: CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWC…
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM #VisualAbstract by @kidney_boy #ISNWCN
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes —cited by Dr. Joel Topf, MD, FACP, St. Clair University @kidney_boy #KidneyCon “There was an amputation signal... we’ll talk more about that later.” https://t.co/rkEebrP0h8
15/15 Links to citations: https://t.co/MVMmAtpIaf https://t.co/PY4Dn6X9Bn https://t.co/VX44qck2n2 https://t.co/s2GQbKKI3R https://t.co/meSES5A9HF https://t.co/Poio86DZ74 https://t.co/aneU63NacY
RT @CristobMorales: @ValleAlfonso @secardiologia @almucastro01 @jlgorriz @vic_pallares @rafavidalperez @mendez_bailon @paolabel_cardio @cri…
http://www.nejm.org/doi/full/10.1056/NEJMoa1611925
#CANVAS looks like a smaller effect size than Emma-ref but overall delighted to see a second outcome trial that's + http://www.nejm.org/doi/full/10.1056/NEJMoa1611925
40% reduction in GFR, that's a new one. Anyone know where that came from? #CANVAS http://www.nejm.org/doi/full/10.1056/NEJMoa1611925
DOI: 10.1056/NEJMoa1611925 “Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. Outcomes Patient characteristics DOI: 10.1056/NEJMoa1611925.
org/doi/full/10.1056/NEJMoa1611925 قناة جدد معلوماتك الدوائية على التليجرام T.me/FYIMs @FYIMs. Brak dostępnego opisu zdjęcia. Zouhour K Jouny i 11 innych ...
Articulo completo: http://www.nejm. org/doi/full/10.1056/NEJMoa1611925?query=feature d_home#t=articleMethods · Canagliflozin and Cardiovascular and Renal ...
org/doi/full/10.1056/NEJMoa1611925 https://www.nejm. org/doi/full/10.1056/NEJMoa2024816 https://www.nejm. org/doi/full/10.1056/NEJMoa1811744 https://www ...
... or metatarsal. www.nejm.org/doi/full/10.1056/NEJMoa1611925 · No photo description available. Nuha Abdalla and 14 others ·
3. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611925. PubMed.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611925. PubMed. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611925 . )| false. Export Citation. 4. https://www ...
doi:10.1056/nejmoa1611925. 11. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N ...
Cardiologist-Sorbonne University. EAS executive committee. Associate editor Arch.of Med Sc (IF3.5)-Minerva CardiolAngio (IF1.4)-Advances in ...
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925; Zinman B, ...
18 likes, 0 comments - farmaco.logicas on November 13, 2024: "Você sabe como os medicamentos utilizados para tratamento da Diabetes Mellitus ...
... 10.1056/NEJMoa1611925). Schließlich konnte Metformin in der HARMONY-Studie, die den GLP-1-RA Albiglutid untersuchte, die drei »Major Adverse ...
2017;doi:10.1056/NEJMoa1611925. Published by: cardiology today logo. Sources/Disclosures. Source: Bonaca MP. Session 3 – ...
doi:10.1056/NEJMoa1611925. 3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med ...
... 10.1056/NEJMoa1611925. QASEEM, A., et al. Oral pharmacologic ... 10.1056/NEJMoa1611925. ZACCARDI, F., et al. Efficacy and safety of ...
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925. 15. Perkovic ...
doi:10.1056/NEJMoa1611925. 4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med ...
doi:10.1056/NEJMoa1611925. Perkovic, Vlado et al. “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.” The New England ...
... 10.1056/nejmoa1504720 DECLARE TIMI https://www.nejm.org/doi ... org/doi/full/10.1056/NEJMoa1611925 DAPA-HF https://www.nejm. org/doi ...
... 10.1056/NEJMoa1811744 #5 Canagliflozin-Renal-CREDENCE https://www.nejm.org/doi/full/10.1056/NEJMoa1611925 #6 Canagliflozin-CAD-Canvas https ...
doi: 10.1056/NEJMoa1611925. Wiviott SD, Raz I, Bonaca MP et al. New Engl J Med 2019;380:347–357. doi: 10.1056/NEJMoa1812389.
2017;doi:10.1056/ NEJMoa1611925. Rosenstock J, et al. Diabetes Care. 2018;doi:10.2337/dc18-1749. Wiviott SD, et al. N Engl J Med. 2019;doi ...
doi: 10.1056/NEJMoa1611925. 7. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes ...
DOI: 10.1056/NEJMoa1611925. 9. Kosiborod M, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus ...
... 10.1056/NEJMoa1611925. [Epub ahead of print]. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. Neal B, Perkovic V ...
This recommendation is coming based off of the [CANVAS-R Trial] (http://www.nejm.org/doi/full/10.1056/NEJMoa1611925#t=article) findings that ...
New England Journal of Medicine, 2017; DOI: 10.1056/NEJMoa1611925. Cite This Page: MLA; APA; Chicago. George Institute for Global Health. "Major ...
DOI: 10.1056/NEJMoa1611925. Newsletter. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of ...
EL
IN
S
MF
S
JO
ま
ゆ
JF
GG
CM
N
YU
E
DO
R
AO
CT
FE
JS
パ
た
L
R
NM
D
LN
CG
MF
F
DO
WA
CC
MV
VC
SA
AM
RG
CL
EL
FL
RC
AA
SS
PJ
RD
MA
SF
BG
LA
M
AR
SH
TS
BD
DC
PT